Charles River Laboratories International, Inc.’s stock price dips to $194.31, marking a 3.31% decline

Charles River Laboratories International, Inc. (CRL)

194.31 USD -6.66 (-3.31%) Volume: 1.54M

Charles River Laboratories International, Inc.’s stock price stands at 194.31 USD, witnessing a decline of -3.31% in the current trading session with a volume of 1.54M shares traded. The stock’s performance has been underwhelming this year, with a significant drop of -17.80% YTD, indicating a bearish trend for CRL.

Latest developments on Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. (NYSE:CRL) has been experiencing fluctuations in its stock price recently, with analysts issuing mixed forecasts and price targets. Despite a lower price target of $203.00 by TD Cowen, some analysts believe the company is worth US$227. Following its latest results, expectations have been lowered by some analysts, while others have upgraded their rating to “Buy.” Additionally, SG Americas Securities LLC and Park Avenue Securities LLC have increased their positions in the company, showing confidence in its future performance. With UBS Group trimming its target price to $240.00 and Barclays lowering the price target to $210.00, investors are closely monitoring Charles River Laboratories for potential opportunities in the market.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Charles River Laboratories has a mixed long-term outlook. While the company scores well in areas such as value and growth, it lags behind in dividend and resilience. With a strong focus on providing research tools and support services for drug discovery and development, Charles River Laboratories caters to a wide range of customers including pharmaceutical and biotechnology companies, hospitals, and academic institutions.

Despite facing challenges in areas like dividend and resilience, Charles River Laboratories shows promise in terms of value and growth potential. With a solid momentum score, the company may be well-positioned to capitalize on future opportunities in the research and development space. Overall, while there are areas for improvement, Charles River Laboratories‘ diverse customer base and focus on innovation could drive its long-term success in the industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma